A new trial assessing the ability of COYA 302 to slow the progression of ALS will enroll up to 120 patients at sites in the U ...

In a now-completed clinical trial, the stem cell therapy Neuronata-R was found to benefit ALS patients with slower disease progression.

IRVINE, Calif. (KABC) -- A diagnosis of ALS is devastating. The rare neurological disease, also known as "Lou Gehrig's disease" attacks nerve cells responsible for controlling voluntary muscle ...

When the results of the first-ever platform trial for amyotrophic lateral sclerosis (ALS) were published this February, the headlines might have seemed disappointing: four experimental drugs failed to ...

Every year roughly 1,000 Canadians are diagnosed with amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig’s disease). Some 4,000 Canadians are currently living with the disease. There are few ...

Typically, the goal of ALS treatments is to slow the disease or halt progression. But new data from the antisense oligonucleotide (ASO) jacifusen for FUS-ALS show that two patients went beyond the ...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe ...

ALS is a difficult disease to diagnose, and researchers say they’ve found clues in the blood that can help with early ...

Following a diagnosis, a Pennsylvania woman underwent genetic testing that revealed she had a very rare, inherited form of ALS — a diagnosis only about 500 people in the U.S. share.